<?xml version="1.0" encoding="UTF-8"?>
<p id="Par62">Multimeric-001 (M-001) is a vaccine currently being developed by BiondVax Pharmaceuticals consisting of nine conserved B and T cell epitopes from HA, nucleoprotein (NP) and matrix 1 (M1) protein arranged in triplicate and put onto a single recombinant protein [
 <xref ref-type="bibr" rid="CR57">57</xref>]
 <italic>.</italic> Phase I/II clinical studies have shown the M-001 vaccine induced both cellular and humoral immunity to influenza A and B strains as a standalone vaccine [
 <xref ref-type="bibr" rid="CR58">58</xref>], and also enhanced seroconversion when used as a primer for elderly patients before inoculation with inactivated trivalent vaccines [
 <xref ref-type="bibr" rid="CR85">85</xref>].
</p>
